Drug intelligence / Profile preview

BIIB061

Development stage: Phase 2
Lead developer: Biogen
Modality: Small Molecules
Administration: Oral

Overview

BIIB061 is an oral small molecule drug developed by Biogen for the treatment of multiple sclerosis. It acts as a neuroprotectant and remyelination therapeutic by stimulating myelin protein production, potentially promoting the growth and differentiation of oligodendrocyte progenitor cells to restore myelin sheaths in the central nervous system. The drug was investigated primarily as an adjunctive therapy in relapsing forms of multiple sclerosis but development was discontinued after early-phase clinical trials due to insufficient preclinical efficacy on remyelination[1][2][3][6].

Beyond the preview

Go deeper on BIIB061.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIIB061.

Explore the full profile